The Helio Solution to Early Cancer Detection
We harness the power of artificial intelligence and machine learning to predict the presence of cancer earlier.
Multi-Modal × Multi-Omics Integration
Helio's tests generate deeper, richer biological insights using machine-learning technology built on years of multi-modal and multi-omics research. Over the past ten years, our scientists have used artificial intelligence and machine learning to identify unique, proprietary methylation signatures, patterns of DNA methylation, that predict the presence of cancer as early as Stage I. We combine these methylation signatures with protein biomarkers to develop multi-analyte blood tests with greater sensitivity and specificity than current screening methods.
Our research continues to add more data types and features to our bioinformatics pipeline, capturing a wider array of signals and continuously improving our AI.
Optimising DNA Methylation Capture with ECLIPSE™
Helio Genomics has developed a proprietary platform called ECLIPSE, which enables accurate, efficient detection of cell-free DNA methylation patterns from blood, identifying the unique biomarkers that signal cancer, using next-generation sequencing technology.
cfDNA Extraction
Cell-free DNA is extracted from a blood sample.
Library Prep & Enzymatic Conversion
The sample is prepared and enzymatically converted for analysis.
Hybridisation & Capture
Target methylation regions are captured.
Pooling & Sequencing
Samples are pooled and sequenced using next-generation sequencing.
Watch the Video to Learn More
Identifying epigenetic modifications leads to earlier cancer detection.
Published in Nature Materials.
Read the ArticleWhat's Next for Helio?
With HelioLiver developed and commercially available, Helio's pipeline includes HelioLiver 2.0, the next generation of the test, along with minimal residual disease and treatment-monitoring tests for HCC. Our AI-based methods for early cancer detection are built on a robust research and development programme, drawing on an extensive patient sample bank for validation.
HelioLiver 2.0
The next generation of the test.
Minimal Residual Disease
Tests for HCC.
Treatment Monitoring
Tests for HCC.